AmeriFlex Group
ALNY icon

AmeriFlex Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

AmeriFlex Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-15
Closed -$4.52K – 1256
2026
Q2 		$4.52K Buy
15
+6
+67% +$1.81K ﹤0.01% 1053
2026
Q1 		$2.98K Hold
9
– – ﹤0.01% 911
2025
Q4 		$3.58K Sell
9
-61
-87% -$27K ﹤0.01% 907
2025
Q3 		$31.9K Buy
+70
New +$28.5K 0.01% 548

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

AmeriFlex Group's ALNY Position: Q3 2026 in Review

AmeriFlex Group sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2026, closing a stake of 15 shares — an estimated $4.52K sold.

AmeriFlex Group first reported a position in ALNY in Q3 2025 and held it in 4 quarters. The position peaked at $31.9K in Q3 2025. 591 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

  • AmeriFlex Group reported no remaining Alnylam Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • AmeriFlex Group sold 15 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $4.52K.
  • AmeriFlex Group first reported a position in Alnylam Pharmaceuticals in Q3 2025 and held it in 4 quarters.
  • AmeriFlex Group's Alnylam Pharmaceuticals position peaked at $31.9K in Q3 2025.
  • 591 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on AmeriFlex Group's 13F filing for Q3 2026, filed 13 Nov 2026.